1. Home
  2. IMRN vs TLPH Comparison

IMRN vs TLPH Comparison

Compare IMRN & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • TLPH
  • Stock Information
  • Founded
  • IMRN 1994
  • TLPH 2005
  • Country
  • IMRN Australia
  • TLPH United States
  • Employees
  • IMRN N/A
  • TLPH N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • TLPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMRN Health Care
  • TLPH Health Care
  • Exchange
  • IMRN Nasdaq
  • TLPH Nasdaq
  • Market Cap
  • IMRN 15.0M
  • TLPH 13.4M
  • IPO Year
  • IMRN N/A
  • TLPH 2011
  • Fundamental
  • Price
  • IMRN $1.91
  • TLPH $0.80
  • Analyst Decision
  • IMRN Strong Buy
  • TLPH Strong Buy
  • Analyst Count
  • IMRN 1
  • TLPH 2
  • Target Price
  • IMRN $5.00
  • TLPH $4.50
  • AVG Volume (30 Days)
  • IMRN 7.2K
  • TLPH 71.4K
  • Earning Date
  • IMRN 10-22-2024
  • TLPH 11-06-2024
  • Dividend Yield
  • IMRN N/A
  • TLPH N/A
  • EPS Growth
  • IMRN N/A
  • TLPH N/A
  • EPS
  • IMRN N/A
  • TLPH N/A
  • Revenue
  • IMRN $3,271,194.00
  • TLPH $398,000.00
  • Revenue This Year
  • IMRN N/A
  • TLPH N/A
  • Revenue Next Year
  • IMRN N/A
  • TLPH N/A
  • P/E Ratio
  • IMRN N/A
  • TLPH N/A
  • Revenue Growth
  • IMRN 171.67
  • TLPH 57.31
  • 52 Week Low
  • IMRN $1.48
  • TLPH $0.43
  • 52 Week High
  • IMRN $5.96
  • TLPH $1.61
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 28.51
  • TLPH 38.64
  • Support Level
  • IMRN $2.02
  • TLPH $0.76
  • Resistance Level
  • IMRN $2.73
  • TLPH $0.83
  • Average True Range (ATR)
  • IMRN 0.18
  • TLPH 0.07
  • MACD
  • IMRN -0.06
  • TLPH -0.00
  • Stochastic Oscillator
  • IMRN 12.99
  • TLPH 35.26

About IMRN Immuron Limited

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: